Condition: Sickle Cell Disease · Sponsor: CSL Behring
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
This description comes directly from the study's public registry record.
Trial Registration Coordinator · +1 610-878-4697 · clinicaltrials@cslbehring.com
Always discuss trial participation with your own doctor first.
| UAMS Medical Center | Little Rock, Arkansas, United States | Recruiting |
| The Foundation for Sickle Cell Disease | Hollywood, Florida, United States | Recruiting |
| Center for Cancer and Blood Disorders | Bethesda, Maryland, United States | Recruiting |
| Southern Specialty Research | Flowood, Mississippi, United States | Recruiting |
| Jacobi Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07224360